We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11.50 | 0.70% | 1,651.00 | 1,651.00 | 1,652.00 | 1,656.00 | 1,637.00 | 1,650.50 | 4,661,376 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.80 | 68.01B |
From Apr 2019 to Apr 2024
By Kimberly Chin
GlaxoSmithKline PLC has received the U.S. Food and Drug Administration's approval for the drug Nucala, which treats adult and pediatric patients with hypereosinophilic syndrome, a type of blood disorder.
Nucala will become the first and only targeted biologic treatment to win approval for patients with eosinophil-driven disease in the U.S., the company said. Eosinophils are a type of white blood cell.
The FDA's approval follows a review of data from the company's Phase 3 study, GlaxoSmithKline said. The results showed 50% fewer patients experienced worsening symptoms or required an escalation in treatment compared with the use of a placebo, the company said.
The results were recently published in the Journal of Allergy and Clinical Immunology.
Nucala is currently used as treatment for several other eosinophil-driven diseases.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
September 25, 2020 17:03 ET (21:03 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
